Akynzeo (netupitant/palonosetron) — Point32Health
prevention of nausea and vomiting associated with cancer chemotherapy
Initial criteria
- Akynzeo is being requested for the prevention of nausea and vomiting associated with cancer chemotherapy
- Patient age ≥ 18 years
- Patient is receiving moderately to highly emetogenic intravenous chemotherapy as defined by NCCN Clinical Practice Guidelines for Antiemesis
- Akynzeo will be taken with dexamethasone